Randomised induction and post induction therapy in older patients (greater than or equal to 61 years of age) with Acute Myelocytic Leukaemia (AML) and Refractory Anaemia with Excess of Blasts (RAEB, RAEB-t) Not provided at time of registration

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Randomised induction and post-induction therapy in adult patients (less than or equal to 60 years of age) with acute myelocytic leukaemia (AML) or refractory anaemia with excess of blasts (RAEB, RAEB-t) with IPSS score greater than or equal to 1.5 Not provided at time of registration

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

An open label randomised controlled study in elderly subjects with previously untreated acute myelogenous leukaemia, comparing treatment groups randomised to receive daunorubicin and cytarabine or daunorubicin, cytarabine and PSC-833 Not provided at time of registration

• Pays Netherlands
• Organes Aucun
• Spécialités Aucune

Risk adapted treatment of Acute Myelocytic Leukaemia (AML) Not provided at time of registration

• Pays Netherlands
• Organes Aucun
• Spécialités Aucune

Reduced intensity chemotherapy given with and without imatinib mesylate in patients >/= 60 years considered unfit for standard chemotherapy with previously untreated acute myeloid leukemia (AML) and refractory anemia with excess of blasts (RAEB), refractory anemia with excess blasts in transformation (RAEB-T): a randomized phase II study Not provided at time of registration

• Pays Aucun
• Organes Aucun
• Spécialités Aucune